PHARMIWEB: CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy

PHARMIWEB: CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy

Final patient receives ProtheraCytes(R) cell therapy to regenerate damaged heart tissue following severe heart attack. Study remains on track for final readout in H1 2024

PHARMIWEB.COM | Global Pharma News & Resources – 21 September 2023

Read on line